Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)

Affiliation auteurs!!!! Error affiliation !!!!
TitreNab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)
Type de publicationJournal Article
Year of Publication2015
AuteursBachet J.B, Hammel P., Desrame J., Chibaudel B., Debourdeau P., Dauba J., Lecomte T., Seitz J.F, Tournigand C., Aparicio T., V. Meyer G, Taieb J., Volet J., Bonnetain F., Louvet C.
JournalEUROPEAN JOURNAL OF CANCER
Volume51
PaginationS453-S454
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0959-8049
DOI10.1016/S0959-8049(16)31271-0